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Abstract Inflammatory lesions in the central nervous
system of patients with neuromyelitis optica are charac-
terized by infiltration of T cells and deposition of
aquaporin-4-specific antibodies and complement on astro-
cytes at the glia limitans. Although the contribution of
aquaporin-4-specific autoantibodies to the disease process
has been recently elucidated, a potential role of aquaporin-
4-specific T cells in lesion formation is unresolved. To
address this issue, we raised aquaporin-4-specific T cell
lines in Lewis rats and characterized their pathogenic
potential in the presence and absence of aquaporin-4-
specific autoantibodies of neuromyelitis optica patients.
We show that aquaporin-4-specific T cells induce brain
inflammation with particular targeting of the astrocytic glia
limitans and permit the entry of pathogenic anti-aquaporin-
4-specific antibodies to induce NMO-like lesions in spinal
cord and brain. In addition, transfer of aquaporin-4-specific
T cells provoked mild (subclinical) myositis and interstitial
nephritis. We further show that the expression of the
conformational epitope, recognized by NMO patient-
derived aquaporin-4-specific antibodies is induced in
kidney cells by the pro-inflammatory cytokine gamma-
interferon. Our data provide further support for the view
that NMO lesions may be induced by a complex interplay
of T cell mediated and humoral immune responses against
aquaporin-4.
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Introduction
Inflammatory lesions in the central nervous system (CNS)
of patients with neuromyelitis optica (NMO) are charac-
terized by infiltration of T cells and deposition of
aquaporin-4 (AQP-4)-specific antibodies and complement
on astrocytes at the superficial and perivascular glia limi-
tans. Several lines of evidence suggest that T cells are not
just innocent bystanders of lesion pathogenesis, but that
they are actively involved in this process:
First, AQP-4-specific antibodies and complement
components are unable to cross through the endothelial
blood–brain barrier in the absence of activated, CNS antigen-
specific T cells [5], but they can cause tissue damage if the
blood–brain barrier is by-passed by direct injection of these
molecules into the CNS parenchyma [32]. Secondly, the
leaky phenotype of the blood–brain barrier in immature rats
is not enough to allow AQP-4-specific antibodies to initiate
complement-mediated tissue damage in the absence of
encephalitogenic T cells [5]. Thirdly, even in circumven-
tricular organs characterized by a lack of tight junctions
between endothelial cells, these molecules seem to be unable
to enter in sufficiently high concentrations to cause tissue
damage in the absence of inflammation [5].
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Further evidence for a critical role of T cells in NMO
comes from observations in Japanese NMO patients, where
T cell receptors using the Vb1 or Vb13 chain were clonally
expanded [38]. T cell recognize ‘‘their’’ specific antigen in
context with major histocompatibility complex (MHC)
class I or II products, which show an association with
NMO in some patient cohorts. For example, in AQP-4-
antibody-positive Japanese patients with opticospinal
multiple sclerosis [23], which also belong to the group
of NMO spectrum diseases, the phenotypic frequency
of the human leukocyte antigen (HLA) class II allele
HLA-DPB1*0501 is significantly increased [23], while in
Brazilian Mulatto NMO patients, the HLA-DRB1*03 allele
group is overrepresented [6].
All these different observations suggest that T cells may
play a crucial role in the initiation and/or progression of
NMO. However, the antigen specificity of these cells is
unknown: on the one hand, it was hypothesized that AQP-
4-specific T cells might be present and activated in NMO
patients [8], on the other hand, it was assumed that toler-
ance induction due to the presence of AQP-4 in peripheral
organs might interfere with the activation and expansion of
encephalitogenic T cell responses against this antigen, or
that AQP-4-specific T cells might cause inflammation in
peripheral organs as well. In this study, we specifically
addressed this issue, using the Lewis rat as a model system




Lewis rats were obtained from Charles River Wiga
(Sulzfeld, Germany) and used at an age of 8 weeks
(*170 g body weight). They were housed in the Decentral
Facilities of the Institute for Biomedical Research (Medi-
cal University Vienna) under standardized conditions.
The experiments were approved by the Ethics Commission
of the Medical University Vienna and performed with
the license of the Austrian Ministry for Science and
Research.
Sources and characterization of patient-derived
immunoglobulin preparations
All immunoglobulin preparations from NMO, MS, or
control patients have been described before [5], and are
used here according to the former nomenclature. Unless
otherwise indicated, experiments were performed with the
anti-AQP-4 antibody containing human NMO-IgG derived
from patient J0 [5]. The use of the patients’ plasma for this
study was approved by the Ethics Committee of Tohoku
University School of Medicine (No. 2007-327).
Antigens
For immunization and T cell isolation/propagation, the
following peptides and fusion proteins were used: (1) AQP-
4207–232 (YTGASMNPARSFGPAVIMGNWENHWI con-
taining the putative RT1.BL-binding epitope AQP-4220–228
(PAVIMGNWE)), which was synthesized by Centic Bio-
tech (Weimar, Germany), (2) a thioredoxin fusion protein
containing the C-terminal, intracellular human AQP-4
peptide AQP-4277–322 (MEVEDNRSQVETDDLILKPG
VVHVIDVDRGEEKKGKDQSGEVLSSV) expressed in
E. coli using the pBAD/TOPO ThioFusion Expression
System (Invitrogen, Carlsbad, CA, USA). The expression
of the AQP-4277–322 thioredoxin fusion protein was induced
by arabinose and the recombinant protein was purified by
affinity chromatography on Ni–NTA agarose columns
(Qiagen, Hilden, Germany) under denaturing conditions
(8 M urea, 100 mM NaH2PO4, 10 mM Tris–HCl). This
fusion protein includes the epitope hAQP-4296–304
(GVVHVIDVD), (3) hAQP-4296–304 (GVVHVIDVD),
synthesized by Centic Biotech, (4) guinea pig myelin basic
protein (MBP; Sigma, Vienna, Austria), (5) ovalbumin
(OVA, Sigma).
Immunization and T cell line preparation
Animals were subcutaneously immunized with 100 ll of a
1:1 mixture of the relevant antigen (stock 2 mg/ml) in
Freund0s incomplete adjuvants supplemented with 4 mg/ml
mycobacterium tuberculosis H37Ra. After 9–11 days of
immunization, the animals were killed. At this point, they
were all clinically healthy and did not show any evidence
for inflammation of the CNS or of peripheral organs. The
lymph nodes draining the immunization site were removed,
and peptide-specific T cell lines were established as
described [2]. These lines represent a mixed population of
antigen-specific CD3?/CD4? T lymphocytes which
belonged to the T-helper 1 subset of T cells, as indicated by
strong expression of IL-2 and IFN-c which was similar in
AQP-4277–322- and AQP-4207–232-specific cells (data not
shown).
EAE induction and tissue preparation
Experimental autoimmune encephalomyelitis (EAE) was
induced in Lewis rats by intraperitoneal transfer of
3.5–7 9 107 activated T cells. On day 4 after T cell
transfer, some animals were left untreated, while others
received an additional, intraperitoneal injection with 1-ml
phosphate buffered saline (PBS) and 10 mg anti-AQP-4
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antibody containing NMO-IgG or 10 mg/ml commercially
available human IgG (Subcuvia, Baxter, Vienna, Austria).
This amount of IgG transferred is well tolerated by rats [5,
34] 24 h later, the animals were killed with CO2. After-
wards, they were perfused with 4% phosphate buffered
paraformaldehyde (PFA). Brain, spinal cord, and other
tissues were dissected and immersed for another 18 h in
PFA. The PFA-fixed material was routinely embedded in
paraffin. Tissue sections were stained with hematoxylin
and eosin (HE), and with Luxol fast blue.
Immunohistochemistry
All tissue blocks were cut in serial sections, and all staining
were done essentially as described [1], using the following
antibodies: CD3 (T cells; rabbit polyclonal; NeoMarkers,
Fremont, USA); ED 1 (macrophages, microglia; mouse
monoclonal; Serotec, Germany); OX 6 (MHC class II; mouse
monoclonal, Serotec, Germany); commercial anti-AQP4
(rabbit polyclonal; Sigma, Germany); anti-AQP4-antibody
containing NMO-IgG; anti-GFAP (rabbit polyclonal; Dako,
Denmark, or mouse monoclonal; NeoMarkers); anti-human
Ig (biotinylated donkey; polyclonal; GE Healthcare/
Amersham, Vienna, Austria), anti-complement C9 (rabbit
polyclonal [28]). Immunohistochemistry was completed
using biotinylated secondary antibodies (sheep anti-mouse,
donkey anti-rabbit, or donkey anti-sheep/goat, all from GE
Healthcare/Amersham), and subsequent incubation of the
sections with peroxidase labeled avidin (Sigma).
When anti-AQP4-antibody containing NMO-IgG in a
stock concentration of 10 mg/ml was used for immunohis-
tochemistry on frozen kidney sections, it was first diluted
1:10 in 10%FCS/PBS, mixed with 40 mg rabbit liver powder
(RLP) (Sigma), and incubated for 1 h at room temperature.
Afterwards, the antibody preparation was centrifuged
(10 min, 13,000 rpm, room temperature). Subsequently, the
supernatant was mixed with 25 mg RLP, incubated for 1 h at
room temperature and centrifuged (10 min, 13,000 rpm,
room temperature). Then, the supernatant was mixed with
20 mg RLP, incubated over night at 4C, then for 1 h at room
temperature, and centrifuged (10 min, 13,000 rpm, room
temperature). Finally, the supernatant was diluted with 10%
FCS/PBS to a final concentration of 1:200–1:400 and applied
onto the tissue sections. Immunohistochemistry was com-
pleted with biotinylated sheep anti-human immunoglobulin
and streptavidin-Cy2.
Quantitative evaluation of immunostained sections
and statistic evaluation
Quantification was done by manual counting. We used
whole renal cross sections to count collecting ducts which
had at least 75% of their surface covered by T cells or
macrophages. In addition, we counted collecting ducts
which were invaded by T cells or macrophages. Statistics
was calculated with the Statgraphics Plus program. Mann–
Whitney (Wilcoxon) W test (comparison of medians) was
used in all cases.
PCR analysis of connective tissue, T cells
and microglia cells/perivascular macrophages
to determine mRNA expression of AQP-4
We isolated RNA from the omentum, from established T
cell lines, and from microglia cells/perivascular macro-
phages and astrocytes derived from the fetal brain, using
the RNeasy kit (Qiagen, Hilden, Germany) according to the
instructions of the manufacturer. This RNA was tran-
scribed to cDNA and then subjected to PCR analysis, using
primers specific for AQP4 (forward 50-ACTGGGAAA
ACCATGGATATATTG-30; reverse 50-AGATAATACCT
CTCCAGACGAGTCC-30), and b-actin (forward 50-ATGA
AGTGTGACGTTGACATCC-30; reverse 50-CAAAAATG
AAGTATTAAGGCGG-30) or GAPDH (forward 50-GGCA
TTGCTCTCAATGACACC-30; reverse 50-TGAGGGTGC
AGCGAACTTTAT-30).
For PCR reactions, 5 ll 109 PCR buffer (200 mM
Tris–HCl, pH 8.4, 500 mM KCl), 1 ll 10 mM dNTP mix,
1 ll forward primer (100 pmol/ll), 1 ll reverse primer
(100 pmol/ll), 0.4 ll polymerase (5 U/ll), 1 ll cDNA and
40.6 ll H2O were mixed together. The reaction mix was
heated for 11 min at 95C (denaturation), and then sub-
jected to 40 cycles of denaturation (30 s, 95C), annealing
(30 s, 55C for AQP-4; 53C for b-actin) and elongation
(30 s, 72C). The final extension was made for 10 min at
72C. The size of the resulting PCR products (287 bp for
AQP4, 303 bp for b-actin, and 311 bp for GAPDH) was
determined by agarose gel electrophoresis. Our PCR
reactions and subsequent sequencing analysis of the
amplified products revealed the presence of AQP-4 mes-
sage in astrocytes, and its absence in the omentum, T cells,
and microglia cells/perivascular macrophages (data not
shown).
Production of astrocyte cultures
0–24 h-old Lewis rats were killed, their brains dissected
and transferred to RPMI 1640/10% fetal calf serum (FCS).
After stripping of the meninges, the brains were mechan-
ically dissociated by gentle pipetting. The resulting single
cell suspensions were cultured for 5–7 days in poly-L-
lysine-coated culture flasks, using RPMI 1650/10% FCS,
changing the medium every other day. After this time
period, the mixed glial cell cultures consisted of a mono-
layer of astrocytes and fibroblasts. On top of this
monolayer, loosely adherent, ramified microglial cells and
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glial progenitor cells were found. Confluent mixed glial
cultures were agitated for 12–15 h (180 rpm, 37C). Then,
the supernatant was discarded, and the firmly adherent cells
(mostly astrocytes and fibroblasts) were rinsed with PBS,
trypsinized, re-seeded onto poly-L-lysine-coated cover slips
(for studies on MHC class II and AQP-4 expression by
immunocytochemistry) or 96 well plates (for usage as
antigen-presenting cells), and cultured for an additional
1 day in RPMI 1640/10% FCS prior to their treatment.
Based on GFAP staining, at least 95% of all cells in these
cultures were astrocytes, the remaining cells mostly men-
ingeal fibroblasts.
IFN-c treatment and characterization of astrocytes
For the treatment, each cover slip was transferred to a
separate well of a 12-well plate and inverted. Small dots of
paraffin served as spacers between the cell layer of the
cover slip and the bottom of the 12-well plate. The astro-
cytes growing on the cover slip were either left untreated as
a control, or received IFN-c (100 ng/ml) for 72 h. After-
wards, the cover slips were fixed with 4% PFA for 15 min
(room temperature), washed with 0.05 M Tris-buffered
saline (TBS) (pH 7.4) and permeabilized with TBS con-
taining 0.5% Triton X-100, 5% bovine serum albumin
(BSA, Sigma) and 5% donkey serum (Sigma) for 30 min at
room temperature. The cells were then washed twice with
TBS and incubated overnight at 4C with either OX6
(murine monoclonal against MHC class II, Serotec) or with
commercial rabbit anti-AQP-4 antibody and mouse anti-
GFAP antibody (both diluted 1:100 in TBS/1% donkey
serum). Afterwards, the cells were washed three times with
TBS and incubated for 1 h at room temperature with
donkey anti-mouse Cy2 (for OX6) or with donkey anti-
mouse Cy3 (Jackson Immuno Research Laboratories, West
Grove, PA, USA, for AQP-4) and donkey anti-rabbit Cy2
(Jackson Immuno Research Laboratories for GFAP), all
diluted 1:100 in TBS/1% donkey serum). The cells were
washed with TBS and mounted with gallate/geltol.
Antigen presentation by IFN-c-treated astrocytes
The ability of astrocytes cultured in the absence or pres-
ence of 100 ng/ml IFN-c for 72 h prior to the experiment
to act as antigen-presenting cells of endogenous AQP-4 or
exogenously added AQP-4 peptides was determined using
these astrocytes seeded into flat bottomed 96-well plates at
a density of 1 9 104 cells/well. Prior to their use as anti-
gen-presenting cells, the astrocytes were irradiated with
30 Gray. 5 9 105 T cells were added to give a final volume
of 200 ll/well. Then, the cells were cultured in the pres-
ence or absence of antigen, and T cell proliferation was
determined essentially as described [11].
IFN-c treatment and characterization of collecting duct
epithelial cells
Madin–Darby canine kidney (MDCK) cells were cultured in
the presence or absence of 50 ng/ml recombinant canine IFN-
c (R&D Systems) for the last 72 h. Then, the cells were
detached with accutase (PAA Laboratories GmbH, Pans-
ching, Austria) and incubated for 30 min at 4C with human
NMO-IgG (stock 10 mg/ml) or with Subcuvia as human
control IgG. All antibody preparations were used at a dilution
of 1:100 in stain buffer (BD Pharmingen, San Diego, USA).
After incubation, the cells were washed in stain buffer and
incubated for 30 min at 4C with a biotinylated sheep anti-
human antibody (GE Healthcare/Amersham; 1:100). Then,
the cells were washed in stain buffer and incubated for 30 min
at 4C with an allophycocyanin (APC)-labeled anti-biotin
antibody (MACS Miltenyi Biotec, Bergisch-Gladbach,
Germany). Then, the cells were analyzed by flow cytometry.
Analysis of parameters of kidney injury in blood
and urine
Experimental autoimmune encephalomyelitis (EAE) was
induced in Lewis rats by intraperitoneal transfer of 5 9 107
activated AQP4207–232 spec. T cells. On day 4 after T cell
transfer, the animals received an intraperitoneal injection
with 10 mg anti-AQP-4 antibody containing NMO-IgG or
10 mg/ml commercially available human IgG (Subcuvia).
Other animals received either 10 mg anti-AQP-4 antibody
containing NMO-IgG or 10 mg/ml commercially available
human IgG (Subcuvia) without prior T cell injection. 10 h
after antibody injection, the animals were placed for 14 h
in metabolic cages for urine collection, and killed with
CO2. Then, blood was taken from these animals for serum
analysis. We also included untreated animals in this study.
The urine samples were analyzed for the following
parameters: volume/hour, sediment composition, and con-
tent (glucose, leukocytes, erythrocytes, nitrite and proteins,
as analyzed with the Combur5 Test HC (Roche Diag-
nostics, Mannheim, Germany). In the serum, blood urea
nitrogen and creatinine was determined. All these param-
eters were similar in all different experimental groups,
indicating that the inflammatory reactions at the renal
cortico-medullary junction took a subclinical course.
Results
AQP-4 contains epitopes suitable for binding to Lewis
rat MHC class II (RT1.BL)
Informations about possible T cell epitopes on rat AQP-4
were not yet available. However, autoimmune-associated T
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cell responses in Lewis rats are MHC class II RT1.BL
restricted, we used the defined extended RT1.BL-peptide-
binding motif to predict possible T cell epitopes on AQP-4
[39]. According to these predictions, positions 4 and 5 do
not play an important role in RT1.BL binding. Hence, these
positions were neglected in peptide search.
We found two perfect matches: the first optimal binder,
AQP-4220–228, is contained in the extracellular loop E of AQP-
4, which is 100% identical between rats and humans, and
which has the sequence PAVIMGNWE [8]. This sequence
contains glutamic acid (E), a negatively charged residue at
position 9, which is a prerequisite for RT1.BL binding. In
addition to this anchor at position 9, it also contains the aux-
iliary anchors proline (P), valine (V), asparagine (N), and
tryptophan (W) at positions 1, 3, 7, and 8, respectively (Fig. 1).
The second epitope, rAQP-4296–304, is contained in the
intracellular C-terminal part of AQP-4 and had the
sequence GVVHVIDID. This sequence contains aspartic
acid (D), a negatively charged residue at position 9, which
is a prerequisite for RT1.BL binding. In addition to this
anchor at position 9, it also contains the auxiliary anchors
glycine (G), valine (V), aspartic acid (D), and isoleucine
(I, rat) at positions 1, 3, 7, and 8, respectively (Fig. 1).
Because it is easier to obtain rat encephalitogenic T cell
responses with ‘‘foreign’’ CNS antigens, and since in Lewis
rats, T cells specific for guinea pig MBP and bovine S100b
induce a more severe EAE than T cells specific for the
autologous proteins, we used the human counterpart of the
identified epitope, hAQP-4296–304 (GVVHVIDVD) with its
amino acid exchange at position 8. The valine at position 8
of the human sequence is as suitable to bind to RT1.BL as
the isoleucine at position 8 of the rat sequence.
Lewis rats can mount encephalitogenic T cell responses
against AQP-4
When we immunized experimental animals with AQP-4
peptides containing the identified epitopes, we did not see
any evidence for clinical or histologically evident CNS
disease (data not shown). However, we were able to raise
antigen-specific T cell lines.
Transfer of AQP-4207–232-specific T cells did not cause
any clinical signs of EAE (data not shown), although they
induced inflammatory lesions along the entire neuraxis
(Fig. 2), and were highly specific for their cognate antigen
(Fig. 3). In the brain, these lesions were observed in
cerebral and cerebellar cortex, the basal hypothalamus and
the brain stem. Predilection sites for these lesions were the
AQP-4 rich glial lamellae of the basal/lateral hypothala-
mus and the meninges, where the inflammatory cells
formed multilayered, densely packed foci, which were
either located on top of a seemingly intact subpial glia
limitans, or infiltrated the parenchyma from this site
(Fig. 2). The inflammatory lesions were dominated by
T lymphocytes (T cells: macrophages/activated microglia
cell ratio = 4.4). We did not detect any inflammatory
lesions in the optic system. In the spinal cord, inflam-
matory lesions were found at the thoracic as well as at the
lumbar/sacral level and frequently involved the dorsal
horns (Fig. 2). Both in brain and spinal cord, astrocytes
remained intact, and there was no evidence for myelin/
oligodendrocyte injury. When AQP-4207–232-specific T
cells were transferred together with anti-AQP-4 antibody
containing NMO-IgG, lesions were more numerous and
larger. The parenchymal infiltration by T cells (Fig. 4) and
the numbers of macrophages/activated microglia cells was
more pronounced (T cell: macrophages/activated microg-
lia cell ratio = 1.3). AQP-4 loss was readily seen. In the
brain, areas of AQP-4 loss involved the periventricular
pons, subpial cortical areas of the cerebral cortex, and
perivascular sites of cerebellar deep white matter and
medulla (Fig. 4). In the spinal cord, AQP-4 loss mostly
involved the perivascular glia limitans of the gray matter,
and was much less pronounced at the white matter peri-
vascular or subpial glia limitans (Fig. 4). Myelin and
oligodendrocytes remained intact.
Fig. 1 Identification of RT1.BL-peptide-binding motifs of rat AQP-4.
a List of amino acids enhancing or decreasing binding to RT1.BL at
peptide positions 1–9 [39]. Please note that positions 4 and 5 do not
play an important role in RT1.BL binding [39] and were neglected in
peptide search. b Amino acid sequences of two rat AQP-4 nonamers
showing a 100% match to the binding requirements at positions
1,3,7,8, and 9 (red), and of seven rat aquaporin 4 nonamers showing 1
mismatch (green) to the optimal binding motif at these positions.
c Alignment of the completely matching epitopes with rat aquaporin 4
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Transfer of hAQP-4296–304-specific T cells provoked a
subclinical EAE with few inflammatory lesions in the CNS
(Fig. 5). The CNS lesions presented mostly as small foci of
meningeal inflammation, from which T cells entered the
CNS parenchyma via the subpial glia limitans (Fig. 5). The
optic system was not affected, and astrocytes as well as
oligodendrocytes remained intact. Co-transfer of hAQP-
4296–304-specific T cells with anti-AQP-4 antibody con-
taining NMO-IgG did not increase the lesion load in the
CNS, did not increase the parenchymal infiltration of the
CNS by T cells, and was not associated with noticeable loss
of AQP-4 reactivity in the CNS (data not shown). The low
degree of CNS inflammation induced by hAQP-4296–304-
specific T cells coincided with an accumulation of these
cells in the omentum (supplementary fig. 1), although PCR
analysis did not show evidence for AQP-4 expression at
this site (data not shown). The inability of large numbers of
these cells to leave the peritoneal cavity stood in marked
contrast to the behavior of AQP-4207–232-specific T cells or
of any other T cells injected at this site [5, 7, 13] and was
not further analyzed.
The infiltration of AQP-4207–232- and AQP-4296–304-
specific T cells from the subpial glia limitans into the CNS
parenchyma raised the question whether astrocytes could
Fig. 2 CNS inflammation
caused by AQP-4207–232-specific
T cells. a Distribution of
densely packed inflammatory
lesions along the neuraxis, using
schemes provided by Paxinos
and Watson [27] as guide lines.
Brain and spinal cord [cervical
(C1–7), thoracal (T1–10) and
lumbar/sacral (L1–S4)] sections
of eight animals were analyzed,
and the location of each lesion
was projected in red color into
the relevant scheme. 2/8
animals had been injected with
AQP-4207–232-specific T cells
only; 3/8 animals had been
injected with AQP-4207–232-
specific T cells and Subcuvia,
and 3/8 animals had been
challenged with AQP-4207–232-
specific T cells and NMO-IgG.
The data shown here were
obtained from 48 brain sections
and 120 spinal cord sections.
Inflammation of the glial
lamellae of the basal
hypothalamus (b) and the
orbital cortex (c, d).
e Inflammatory cells overlaying
and infiltrating the dorsal horn
of the spinal cord. f–g Massive
build-up of inflammatory cells
on top of an essentially intact
subpial glia limitans of the
spinal cord (d–g). Tissue
sections were stained with
antibodies against AQP-4
(b, d, e, f) or GFAP (c, g),
the nuclei were counterstained
with hematoxylin
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trigger some T cell reactivation at the blood–brain barrier.
To address this question, we first made immunohisto-
chemical analysis of the inflamed CNS, but we were unable
to find any evidence for MHC class II expression on
GFAP? astrocytes (data not shown). However, this still left
us with the possibility that astrocytes in the lesions carry
MHC class II products on the surface, which are below the
limit of detection by conventional immunohistochemistry,
but would nevertheless exert biological functions. There-
fore, we addressed this possibility in in vitro studies. We
treated astrocytes with IFN-c to induce MHC class II
products and used these cells in T cell activation assays
(Fig. 6). We used AQP4207–232-specific T cells in our
assay, since these cells showed a higher encephalitogenic
potential than their AQP-4296–304-specific counterparts,
and because they also showed a deeper infiltration into the
parenchyma. We observed that MHC class II? astrocytes
were able to activate AQP-4207–232-specific T cells only in
the presence of the exogeneously added peptide AQP-
4207–232, but not in its absence (Fig. 6). This observation
suggested that astrocytes were unable to present frag-
ments of endogenous AQP-4 to AQP-4207–232-specific
T cells.
We also observed inflammatory lesions in muscle
(Fig. 7) and kidney (Fig. 8). Because these organs not only
express AQP-4, but also many other AQPs, we first ana-
lyzed whether these other AQPs share sequence homology
to AQP-4220–228- and hAQP-4296–304. This was not the case
(Fig. 9). Hence, these inflammatory lesions must be trig-
gered by the local availability of AQP-4 and appropriate
antigen-presenting cells.
Muscle lesions were observed in 2/6 animals injected
with hAQP-4296–304-specific T cells. The inflammatory cell
population was located in the connective tissue compart-
ment and contained neutrophils and eosinophils. The
muscle fibers themselves were not invaded (Fig. 7). The
real extent of muscle involvement in the AQP-4-specific T
cell injected animals is probably higher, since we only
sampled and analyzed the m. glutaeus.
We also observed kidney inflammation in all animals
injected with AQP-4207–232- and hAQP-4296–304-specific T
cells. This finding was subject of more detailed analysis.
AQP-4207–232- and hAQP-4296–304-specific T cells
profoundly enhance the anti-AQP-4 antibody
containing NMO-IgG induced peri-ductal inflammation
at the renal cortico-medullary junction
The presence of inflammatory cells surrounding and even
infiltrating collecting ducts at the renal cortico-medullary
junction was a common feature of all animals injected
with anti-AQP-4 antibody containing NMO-IgG (Table 1;
Fig. 8). It was not associated with clinically overt kidney
disease or with noticeable changes of the urine (data not
shown). Periductal renal inflammation could be repro-
duced using anti-AQP-4 antibody containing NMO-IgG
from an additional AQP-4 antibody? NMO patient tested
(patient J1 of [5]). It was not observed with IgG prepa-
rations obtained from AQP-4 antibody-negative NMO
patients (patients J3 and J4 of [5]), MS patients (patients
J6 and J7 of [5]), or controls (patients J8 and J9 of [5],
and was also not evident after transfer of Subcuvia
(Table 1).
In the presence of AQP-4207–232- and AQP-4296–304-
specific T cells, the AQP-4 antibody-induced peri-ductal
inflammation at the renal cortico-medullary junction was
Fig. 3 Antigen specificity of AQP-4207–232-specific T cells. 5 9 10
5
AQP-4207–232-specific T cells were cocultured in triplicates with
1 9 106 thymic antigen-presenting cells in the absence of externally
added antigens (0), or in the presence of myelin basic protein (MBP, as
irrelevant CNS antigen), AQP-4207–232 representing AQP-4 loop E (E),
myelin oligodendrocyte glycoprotein (MOG, as second irrelevant CNS
antigen) or concanavalin A (ConA, as positive control) (upper panel).
In a second set of experiments, 5 9 105 AQP4207–232-specific T cells
were cocultured in triplicates with 1 9 106 thymic antigen-presenting
cells in the absence of externally added antigen (0), or in the presence of
AQP-454–71 representing AQP-4 loop A (a), AQP-4137–157 representing
AQP-4 loop C (C), AQP-4207–232 representing AQP-4 loop E (E), AQP-
4277–322 representing the C-terminal, intracellular domain of AQP-4
(ic), ovalbumin (OVA, as an irrelevant antigen), or ConA as positive
control. T cell activation, as evidenced by incorporation of 3H
thymidine, and measured in counts per minute (cpm) was only detected
upon exposure to AQP-4207–232 and in response to ConA. Shown here
are the mean values of cpm ± standard deviation
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exacerbated, while only low numbers of inflammatory cells
were observed at this site when AQP-4207–232- and AQP-
4296–304-specific T cells had been injected into the recipient
animals (Fig. 8). T cells were essentially undetectable at
the cortico-medullary renal junction upon transfer of OVA-
or MBP-specific T lymphocytes (Table 1). The peri-ductal
inflammation provoked by anti-AQP-4 antibody containing
NMO-IgG remained detectable upon transfer of OVA-
specific T cells, but was completely abolished in the
presence of MBP-specific T cells (Table 1). This finding
cannot be explained by a selective depletion of antibodies
by astrocytes in the course of severe CNS inflammation,
since animals injected with NMO-IgG only and animals
injected with MBP-specific T cells and NMO-IgG had
comparable antibody titers in the serum (both in the range
of 1:512–1:1,024).
In collecting ducts of the intact kidney, AQP-4 could be
readily detected with the commercial antibody directed
against an intracellular epitope of this molecule, while the
binding efficiency of the pathogenic anti-AQP-4 antibod-
ies contained in our NMO-IgG preparations was very low
(Fig. 8). Moreover, in the presence of these pathogenic
antibodies alone, the degree of peri-ductal inflammation at
the renal cortico-medullary junction was lower than the
one observed in the presence of both AQP-4-specific T
cells and AQP-4-specific autoantibodies. These two
observations raised the question whether an inflammatory
milieu provoked by kidney-infiltrating T cells could lead
to an enhanced exposure/availability of AQP-4 epitopes
recognized by the pathogenic anti-AQP-4 antibodies from
human NMO patients. To specifically address this ques-
tion, we used the canine collecting duct cell line MDCK
Fig. 4 AQP-4 loss caused by the combined action of AQP-4207–232-
specific T cells and NMO-IgG. Subpial (a) and perivascular (b) loss
of AQP-4 reactivity. Consecutive sections of lumbar spinal cord. Note
the presence of large numbers of inflammatory cells (c), the
dominance of granulocytes in the infiltrate (d), the presence of
macrophages with degradation products (red e), and the massive loss
of AQP-4 reactivity in the tissue (f). The inflammatory lesion is
associated with the presence of human IgG (g) and with the
deposition of complement (h). Tissue sections were stained with
antibodies against AQP-4 (brown a, b, f) analyzed by hematoxylin/
eosin (c, d) or Luxol fast blue staining (myelin blue, degradation
products red e), or anti-human IgG (brown g) or anti-C9neo (red h).
The nuclei were counterstained with hematoxylin
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[10] for further studies. This was possible since the three
AQP4 extracellular loops A, C, and E participate in the
formation of the NMO-IgG epitope [29], and since these
loops are highly conserved in human, rat, and canine
AQP-4. We cultured MDCK cells in absence and presence
of IFN-c, and studied the expression of AQP-4 on these
cells by flow cytometry. In the absence of IFN-c, binding
of anti-AQP-4 antibody containing NMO-IgG to the sur-
face of MDCK cells was below the limit of detection.
However, binding of this antibody was observed when
the cells had been cultured in the presence of IFN-c
(Fig. 8).
Discussion
Our study provides insights, which may be relevant for the
pathogenesis of NMO. It first shows that AQP-4-specific T
cells are part of the normal immune repertoire of rats and,
following expansion and activation can induce T cell-
mediated brain inflammation, which is sufficient for AQP-
4-specific antibodies to reach the brain and to initiate
NMO-like lesions in the CNS. Secondly, it provides evi-
dence that organs with high AQP-4 expression other than
the CNS, such as kidney and muscle, may be affected by
the disease process.
Fig. 5 CNS inflammation
caused by hAQP-4277–322- and
hAQP-4296–304-specific T cells.
a Distribution of densely packed
inflammatory lesions along the
neuraxis, using schemes
provided by Paxinos and
Watson [27] as guide lines.
Brain and spinal cord [cervical
(C1–7), thoracal (T1–10) and
lumbar/sacral (L1–S4)] sections
of seven animals were analyzed,
and the location of each lesion
was projected in red color into
the relevant scheme. The data
shown here were obtained from
42 brain sections and 140 spinal
cord sections. Inflammatory foci
at the subpial glia limitans of
the brain (b–g) and spinal cord
(h, i) are shown. Please note the
ongoing parenchymal
infiltration in b and f, and the
diffuse distribution of T cells in
the dorsal horns (h). Tissue
sections were stained with anti-
CD3 antibodies to identify T
cells (b, e–i), with the antibody
ED1 to identify macrophages/
activated microglia cells, c or
with anti-AQP-4 antibody (d),
the nuclei were counterstained
with hematoxylin
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Inflammatory lesions in the CNS of NMO patients are
characterized by infiltration of T lymphocytes and depo-
sition of AQP-4-specific antibodies and complement on
astrocytes at the glia limitans [20, 31]. The formation of
antibodies depends on T cell help, but whether or not AQP-
4-specific T cells can also contribute to the inflammatory
process remains an open issue. We show here, that the
normal immune repertoire of Lewis rats harbors AQP-4-
specific T cells, just as the murine immune repertoire does
[12, 24], that AQP-4-specific T cells have encephalitogenic
potential, and that they are able to cooperate with anti-
AQP-4 antibodies to produce astrocyte-destructive lesions.
Myelin/oligodendrocyte loss was not observed, due to the
acute nature of our experiments [5]. The encephalitogenic
potential of our AQP-4-specific T cell lines was low and,
thus, despite the transfer of high numbers of T cells no
clinical deficits were present in the recipient animals. One
possible reason for this observation could be that the nat-
ural processing of AQP4 might preferentially generate
peptides different from those used by us for the isolation of
AQP-4-specific T cells, and this point has to be addressed
in future studies. Nevertheless, our AQP-4 peptide-specific
T cells induced subclinical inflammation in the brain and
spinal cord with a pattern of inflammation unique to this T
cell population. In contrast to S100b-specific T cells, which
recognize another astrocytic protein [15], there was only
very little inflammatory response in the CNS parenchyma.
Instead, the glia limitans was selectively targeted, leading
to characteristic T cell infiltrates between the astrocytic
layers. Moreover, on a background of diffuse T cell infil-
tration, S100b T cell transferred animals showed *13% of
their spinal cord lesions in the dorsal horns, while
AQP4207–232-specific T cell transferred animals had *53%
of spinal cord lesions at this site (data not shown). It has
been shown before in cotransfer models of MOG reactive T
Fig. 6 Astrocytes as antigen-presenting cells. Astrocytes cultured in
vitro for 72 h in the absence (a, c) or presence of IFN-c (b,
d) maintain GFAP (red) and AQP-4 (green) expression. None of the
untreated (c) and approximately 10% of the IFN-c treated astrocytes
(d) express MHC class II products (OX-6 staining red). e Presentation
of exogenous antigens by IFN-c treated astrocytes. When these cells
were cocultured with AQP-4207–232-specific T cells in the absence of
externally added antigens (0), or in the presence of AQP-454–71
representing AQP-4 loop A (A), AQP-4137–157 representing AQP-4
loop C (C), AQP-4207–232 representing AQP-4 loop E (E), AQP-
4277–322 representing the C-terminal, intracellular domain of AQP-4
(ic), myelin basic protein (MBP) as an irrelevant CNS antigen, or
concanavalin A (ConA), T cell activation was only detected upon
exposure to AQP-4207–232 and in response to ConA. Shown in this
graph are differences in the average counts per minute (Dcpm)
obtained from triplicate cultures of T cells challenged with antigens
and IFN-c treated or untreated astrocytes, given as mean ± SD. The
graph is representative of two experiments. f No presentation of
endogenous AQP-4 peptides by IFN-c-treated astrocytes. The average
cpm (mean ± SD) seen when astrocytes were cocultured in triplicates
with AQP-4207–232-specific T cells in the absence of AQP-4207–232
(273.3 ± 110.0) is in the range of the sum of the cpm (mean ± SD)
of astrocytes alone (131.7 ± 42.7) plus AQP-4207–232-specific T cells
cultured with AQP-4207–232 only (137.5 ± 27.6; to reveal carryover
of antigen-presenting cells in the T cell preparation used) or AQP-
4207–232-specific T cells cultured without antigen (64.3 ± 9.1). The
graph is representative of two experiments
c
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cells and demyelinating anti-MOG antibodies [21] as well
as in transfer experiments with human NMO-IgG [3, 5] that
pathogenic antibodies induce lesions, when reaching the
CNS at sites of T cell mediated inflammation. T cell
inflammation leads to opening of the blood–brain barrier,
allowing antibodies and complement to reach the target
tissue [22] and also to the activation of macrophages or
microglia which induce tissue injury through antibody-
dependent cellular cytotoxicity. In the absence of T cell-
mediated inflammation this can be achieved by local
injection of demyelinating antibodies together with IFN-c
[37]. To initiate antibody-mediated damage in the CNS
only a very mild, subclinical T cell mediated inflammation
is required [18], which is also seen in our studies. Our
results, thus, indicate that a T cell-mediated immune
response may be instrumental in the induction of NMO
lesions, even when such a T cell response alone is insuf-
ficient to induce disease. Whether NMO patients mount a T
cell response against AQP-4 and whether such a T cell
response is associated with relapses of the disease has to be
shown in future studies.
Moreover, additional animal models of NMO are nee-
ded, preferentially involving T cell- and B cell-specific
immune responses against AQP-4 and such studies are
warranted by recent observations in an animal model of
spontaneous opticospinal encephalomyelitis involving
MOG-reactive T and B cells which suggest that autoim-
mune T and B cells may interact on several levels to create
disease [16, 30]: Antigen-specific T cells could recruit
endogenous antigen-specific B cells [30], drive their dif-
ferentiation to Ig-producing plasma cells or long-lived
memory B cells [16], and could even control Ig affinity
maturation and isotype switching [16], while antigen-spe-
cific B cells could capture even highly diluted protein
antigens and present them to specific T cells [17].
AQP-4 is highly expressed also in other tissues than the
CNS, such as muscle and kidney. However, so far NMO is
regarded as a CNS-specific disease, leaving other organs
unaffected. This may have one major reason. As we show
in this study, there is only a very low or even absent
expression and/or accessibility of the pathogenic NMO
Fig. 7 Muscle inflammation upon transfer of hAQP-4296–304-specific
T cells (HE staining). Eosinophilic granulocytes are labeled with
white arrowheads, neutrophilic granulocytes with a black arrow
Fig. 8 Renal pathology following the transfer of AQP-4296–304-
specific T cells in combination with AQP-4 antibody containing
NMO-IgG. In the intact kidney (a–c), AQP-4 positive collecting ducts
(brown) are essentially absent in the cortex, appear at the cortico-
medullary junction (a), and are found in high numbers in the renal
papilla (a). Intact collecting duct cells show a basolateral staining
pattern (b, c), which is much stronger, when the commercial anti-AQP-
4 antibody was used (b brown) than it was, when anti-AQP-4 antibody
containing NMO-IgG was utilized (c red). d–e Peri-ductal inflamma-
tion at the renal cortico-medullary junction following transfer of AQP-
4296–304-specific T cells in combination with AQP-4 antibody contain-
ing NMO-IgG. Consecutive sections of the cortico-medullary junction,
stained with HE (d) and commercial anti-AQP-4 (e brown). Inflam-
mation was not seen in the renal papilla, although collecting ducts at this
site expressed high levels of AQP-4 (f brown). g Flow cytometry
analysis revealed that binding of AQP-4 antibody containing NMO-IgG
(gray) to the surface of collecting duct cells (MDCK cells) was below
the limit of detection in the absence of IFN-c. In the presence of IFN-c,
the availability of the antibody-reactive AQP-4 epitope increased, and
AQP-4 antibody containing NMO-IgG could readily bind. In both
cases, binding of Subcuvia (red) served as negative control
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epitope, recognized by the patient’s autoantibodies in
kidney and muscle of normal animals. Since the pathogenic
autoantibodies of NMO patients recognize a conforma-
tional epitope of AQP-4, which depends on clustering of
the protein in orthogonal arrays [25], expression of AQP-4
alone not necessarily implies that the respective cells are a
target in the disease. Here, however, we show a binding of
AQP-4 autoantibodies to kidney collecting duct cells
stimulated with IFN-c. Hence, T cell-mediated inflamma-
tion may lead to a slight induction of expression of AQP-4
targets on the cell surface, or to a loss of surface proteins
interfering with the binding of pathogenic autoantibodies
to AQP-4.
We observed an accumulation of inflammatory cells in
the muscle of 2/6 animals injected with hAQP-4296–304-
specific cells. Transient myositis or rhabdomyolysis could
also be a pathological feature in NMO, because elevated
levels of creatine kinase (CK) as a marker for muscle injury
were recently described in some patients [35], in line with
AQP-4 expression in fast-twitch skeletal muscle fibers
[14].
In the kidney, AQP-4 is expressed at the basolateral
surface of collecting duct epithelial cells [8, 36]. These
ducts are much more frequent in the renal papilla than at
the cortico-medullary junction and yet, peri-ductal
inflammation was almost exclusively confined to the renal
cortico-medullary junction. This is probably due to the
facts that the affinity of antibody-antigen interactions is
lowered under high salt conditions [26], and that collecting
ducts of the papilla have to deal with much higher peri-
cellular salt concentrations than their cortico-medullary
counterparts [19]. This could also provide a rationale for
the absence of peri-ductal inflammation at the renal
cortico-medullary junction in animals injected with MBP-
specific T cells and anti-AQP-4-specific antibody contain-
ing NMO-IgG, and for its presence in animals injected with
the same NMO-IgG preparation in the absence of T cell
transfer: the EAE induced by MBP-specific T cells was
accompanied by a pronounced weight loss of *10% body
weight within 24 h of disease onset (data not shown), and
most of this weight loss can be attributed to dehydration,
which might further enhance the pericellular salt concen-
trations in collecting ducts. Alternatively, dehydration
might also directly downregulate renal AQP-4 expression
[33].
Renal disease in NMO patients has not been described
so far. In addition, in our present experiment animals, no
clinically overt renal disease was seen and urinary analysis
did not show pathological alterations, indicating that AQP-
4-specific T cells with or without NMO autoantibodies
induced a mild and subclinical interstitial nephritis. Inter-
estingly, in humans, interstitial nephritis can take an
asymptomatic course [9], and could escape from diagnosis
using conventional markers of kidney injury [4]. Thus,
kidney inflammation may represent a pathological feature
of NMO previously overlooked in NMO patients and
inflammatory changes in the urine of such patients may not
simply represent urinary tract infection in such patients
with severe neurological disability. Alternatively, we can-
not exclude that T cells specific for different AQP-4
epitopes differ in their tropism to CNS, muscle, and kidney,
or, that T cells with specificities unrelated with AQP4
prepare the field for NMO-IgG induced CNS pathology in
NMO patients.
Fig. 9 Alignment of the amino acid sequence of RT1.BL binding T
cell epitopes of rat AQP-4 with other known AQPs. The following
accession numbers were used to align sequences: AQP-1
(EDL88090.1), AQP-2 (NP_037041.2), AQP-3 (NP_113891.1),
AQP-4 (NP_001135838.1), AQP-5 (NP_036911.1), AQP6
(NP_071517.1), AQP-8 (NP_062031.1), AQP-9 (NP_075249.1),
AQP-12 (NP_001102479.1). a Alignment of AQP-4220–228. The
amino acid sequence of AQP-4220–228 (red) is unique among all
AQPs studied. All other AQP sequences have either amino acid
mismatches (black) or insertions (small letters) at this site. b Align-
ment of AQP-4296–304. The amino acid sequence of AQP-4296–304
(red) is unique among all AQPs studied. All other sequences have
either no significant similarity (-), or just an arbitrary match of four
amino acid within their sequence (AQP-3)
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